title: Thrombin is an important mediator of cyclic coronary blood flow variations due to platelet aggregation in stenosed canine coronary arteries.
authors.affiliation: Department of Medicine (Cardiology Division), University of Texas, Southwestern Medical Center, Dallas 75235.
authors.forename: J F
authors.initials: JF
authors.lastname: Eidt
authors.forename: P
authors.initials: P
authors.lastname: Allison
authors.forename: S
authors.initials: S
authors.lastname: Noble
authors.forename: J
authors.initials: J
authors.lastname: Ashton
authors.forename: P
authors.initials: P
authors.lastname: Golino
authors.forename: J
authors.initials: J
authors.lastname: McNatt
authors.forename: L M
authors.initials: LM
authors.lastname: Buja
authors.forename: J T
authors.initials: JT
authors.lastname: Willerson
mesh_terms: D000818:Animals; D000991:Antithrombins; D001120:Arginine / Q000031:analogs & derivatives; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000209:etiology* / Q000503:physiopathology; D004285:Dogs; D005231:Fatty Acids, Unsaturated; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006834:Hydrazines / Q000494:pharmacology; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D010875:Pipecolic Acids / Q000494:pharmacology; D010974:Platelet Aggregation; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000502:physiology*; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors
chemical_list: D000991:Antithrombins; D019086:Bridged Bicyclo Compounds, Heterocyclic; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines; D010875:Pipecolic Acids; D013449:Sulfonamides; D013928:Thromboxane A2; C045749:SQ 29548; D006493:Heparin; D001120:Arginine; D007650:Ketanserin; D013917:Thrombin; C031942:argatroban